Week In Review: Two Hong Kong IPOs - BeiGene And Ascletis - Raise A Combined $1.3 Billion

BeiGene, a Beijing oncology company, raised $900 million in a debut offering on the Hong Kong stock exchange. Ascletis Pharma of Hangzhou completed a $400 million IPO on the Hong Kong exchange at a $2 billion capitalization